Profil bibliographique

Charlie W. Lees

Informations fournies par OpenAlex. Research Africa ne déduit ni nationalité, ni poste, ni coordonnées personnelles.

415Publications signalées

30115Citations signalées

4Affiliations récentes

Institutions déclarées

NHS Lothian Western General Hospital Edinburgh Cancer Research Institute of Genetics and Cancer

Domaines associés

Inflammatory Bowel DiseaseMicroscopic ColitisBiosimilars and Bioanalytical MethodsHealth, Medicine and SocietyHermeneutics and Narrative Identity

Publications récentes

Accès ouvert 2026 articleOpenAlex

The efficacy and safety of etrasimod as a first-line advanced therapy for ulcerative colitis: prespecified and post hoc subgroup data from the ELEVATE UC clinical program

David T. Rubin, Charlie W. Lees, Filip Baert, Maria Kudela et autres

0 citationsTherapeutic Advances in Gastroenterology

Accès ouvert 2026 preprintOpenAlex

Landmarking with Latent Class Mixed Models for Dynamic Prediction of Time-to-event Data with Heterogeneous Biomarker Trajectories

Víctor Velasco-Pardo, Nathan Constantine‐Cooke, Charlie W. Lees, Catalina A. Vallejos

0 citationsarXiv (Cornell University)

Accès ouvert 2026 preprintOpenAlex

Landmarking with Latent Class Mixed Models for Dynamic Prediction of Time-to-event Data with Heterogeneous Biomarker Trajectories

Víctor Velasco-Pardo, Nathan Constantine‐Cooke, Charlie W. Lees, Catalina A. Vallejos

0 citationsarXiv (Cornell University)

Accès ouvert 2026 articleOpenAlex

HLA-DRB1*01:03 in patients with inflammatory bowel disease: a genotype–phenotype association study

Qian Zhang, Eathar Shakweh, Mohmmed Tauseef Sharip, Benjamin Zaré et autres

3 citationsThe Lancet. Gastroenterology & hepatology

2026 articleOpenAlex

982 RANDOMISED CONTROLLED TRIAL OF WITHDRAWAL OF THIOPURINES WHEN SWITCHING FROM INTRAVENOUS TO SUBCUTANEOUS INFLIXIMAB: RESULTS OF THE MINIMISE STUDY

Peter M. Irving, Andrea Centritto, Xin Yi Choon, Jie Han Yeo et autres

0 citationsGastrointestinal Endoscopy

2026 articleOpenAlex

982 RANDOMISED CONTROLLED TRIAL OF WITHDRAWAL OF THIOPURINES WHEN SWITCHING FROM INTRAVENOUS TO SUBCUTANEOUS INFLIXIMAB: RESULTS OF THE MINIMISE STUDY

Peter M. Irving, Andrea Centritto, Xin Yi Choon, Jie Han Yeo et autres

0 citationsGastroenterology

Accès ouvert 2026 articleOpenAlex

Real-world effectiveness of risankizumab in Crohn’s disease: a pan UK retrospective cohort study

Alexander T. Elford, Nathan Constantine‐Cooke, Krishna Shah, Sarah Faloon et autres

1 citationFrontline Gastroenterology

Accès ouvert 2025 articleOpenAlex

Large-scale Clustering of Longitudinal Fecal Calprotectin and C-reactive Protein Profiles in Inflammatory Bowel Disease

Nathan Constantine‐Cooke, Marie Vibeke Vestergaard, Nikolas Plevris, Karla Monterrubio‐Gómez et autres

1 citationClinical Gastroenterology and Hepatology

Accès ouvert 2025 articleOpenAlex

Effectiveness and safety of upadacitinib in a real-world cohort of patients with Crohn’s disease in the UK: a multicentre retrospective cohort study

Yaa Danso, Chandni Radia, A Elford, Jie Han Yeo et autres

2 citationsBMJ Open Gastroenterology

2025 conference-paperOpenAlex

Symptomatic response trajectories of etrasimod in UC patients: a post hoc analysis of the ELEVATE UC 52 trial

Veit Sollacher, John Woolcott, Charlie W. Lees, Scott A. Jelinsky et autres

0 citationsZeitschrift für Gastroenterologie

2025 articleOpenAlex

Is 2nd JAKi treatment for UC worth the effort? A retrospective, multi-centre UK study

Chandni Radia, Yaa Danso, Susan Ritchie, Melissa F Hale et autres

2 citationsJournal of Crohn s and Colitis

Accès ouvert 2025 articleOpenAlex

Inflammatory Bowel Disease and Risk of More than 1,500 Comorbidities: A Disease-wide Prediagnostic and Postdiagnostic Phenomic Association Study

Anthony Ebert, Bram Verstockt, Martin Bøgsted, Lone Larsen et autres

2 citationsThe American Journal of Gastroenterology

Profil ORCID Notice OpenAlex

BNTIC News n’est pas le producteur de ces données. Recherche à la demande dans Crossref et Europe PMC, sans clé ; OpenAlex reste optionnel. Aucun service payant requis, aucune réponse conservée. Sources et limites.